Strategies to Address Infection Prevention and Treatment in the Reduced Inflammatory Milieu of Irrigated Open Wound

2012 ◽  
Author(s):  
Dean Tsukayama ◽  
Joan Bechtold
2012 ◽  
Vol 23 (7) ◽  
pp. 854-861 ◽  
Author(s):  
Eleanor M. Pritchard ◽  
Thomas Valentin ◽  
Bruce Panilaitis ◽  
Fiorenzo Omenetto ◽  
David L. Kaplan

Marine Drugs ◽  
2019 ◽  
Vol 17 (9) ◽  
pp. 517 ◽  
Author(s):  
Leslie R. Pace ◽  
Zoe L. Harrison ◽  
Madison N. Brown ◽  
Warren O. Haggard ◽  
J. Amber Jennings

Mannitol, a polyalcohol bacterial metabolite, has been shown to activate dormant persister cells within bacterial biofilm. This study sought to evaluate an injectable blend of mannitol, chitosan, and polyethylene glycol for delivery of antibiotics and mannitol for eradication of Staphylococcal biofilm. Mannitol blends were injectable and had decreased dissociation and degradation in the enzyme lysozyme compared to blends without mannitol. Vancomycin and amikacin eluted in a burst response, with active concentrations extended to seven days compared to five days for blends without mannitol. Mannitol eluted from the paste in a burst the first day and continued through Day 4. Eluates from the mannitol pastes with and without antibiotics decreased viability of established S. aureus biofilm by up to 95.5% compared to blends without mannitol, which only decreased biofilm when loaded with antibiotics. Cytocompatibility tests indicated no adverse effects on viability of fibroblasts. In vivo evaluation of inflammatory response revealed mannitol blends scored within the 2–4 range at Week 1 (2.6 ± 1.1) and at Week 4 (3.0 ± 0.8), indicative of moderate inflammation and comparable to non-mannitol pastes (p = 0.065). Clinically, this paste could be loaded with clinician-selected antibiotics and used as an adjunctive therapy for musculoskeletal infection prevention and treatment.


2014 ◽  
Vol 43 (6) ◽  
pp. 36-43
Author(s):  
Rade Panajotović ◽  
Marko Panajotović ◽  
Ljubomir Panajotović

Microbiology ◽  
2018 ◽  
Vol 164 (11) ◽  
pp. 1327-1344 ◽  
Author(s):  
Abraham Majak Gut ◽  
Todor Vasiljevic ◽  
Thomas Yeager ◽  
Osaana N. Donkor

2018 ◽  
Vol 34 (12) ◽  
pp. 2118-2126 ◽  
Author(s):  
Neil Boudville ◽  
David W Johnson ◽  
Junhui Zhao ◽  
Brian A Bieber ◽  
Ronald L Pisoni ◽  
...  

AbstractBackgroundPeritoneal dialysis (PD)-related infections lead to significant morbidity. The International Society for Peritoneal Dialysis (ISPD) guidelines for the prevention and treatment of PD-related infections are based on variable evidence. We describe practice patterns across facilities participating in the Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS).MethodsPDOPPS, a prospective cohort study, enrolled nationally representative samples of PD patients in Australia/New Zealand (ANZ), Canada, Thailand, Japan, the UK and the USA. Data on PD-related infection prevention and treatment practices across facilities were obtained from a survey of medical directors’.ResultsA total of 170 centers, caring for >11 000 patients, were included. The proportion of facilities reporting antibiotic administration at the time of PD catheter insertion was lowest in the USA (63%) and highest in Canada and the UK (100%). Exit-site antimicrobial prophylaxis was variably used across countries, with Japan (4%) and Thailand (28%) having the lowest proportions. Exit-site mupirocin was the predominant exit-site prophylactic strategy in ANZ (56%), Canada (50%) and the UK (47%), while exit-site aminoglycosides were more common in the USA (72%). Empiric Gram-positive peritonitis treatment with vancomycin was most common in the UK (88%) and USA (83%) compared with 10–45% elsewhere. Empiric Gram-negative peritonitis treatment with aminoglycoside therapy was highest in ANZ (72%) and the UK (77%) compared with 10–45% elsewhere.ConclusionsVariation in PD-related infection prevention and treatment strategies exist across countries with limited uptake of ISPD guideline recommendations. Further work will aim to understand the impact these differences have on the wide variation in infection risk between facilities and other clinically relevant PD outcomes.


1999 ◽  
Vol 25 (4) ◽  
pp. 27-28
Author(s):  
M. Rivetti ◽  
F. Galliano ◽  
M. Cotto ◽  
S. Benotto ◽  
A. Bosio

Sign in / Sign up

Export Citation Format

Share Document